<DOC>
	<DOC>NCT00228969</DOC>
	<brief_summary>The primary objective of this study is to evaluate the efficacy, safety, and tolerability of 4 daily doses of RWJ-333369 as adjunctive treatment of refractory partial epilepsy in subjects who are between 18 and 70 years of age, inclusive</brief_summary>
	<brief_title>Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Drug Resistant Epilepsy</mesh_term>
	<criteria>1. Age 1870 years old, 2. Diagnosis of epilepsy for at least 1 year, 3. Presenting, on average, at least 3 partial onset seizures per month, 4. Currently treated with a stable dose (i.e., for at least 4 weeks) of no more than 3 antiepileptic drugs (AEDs), 1. Have experienced status epilepticus in the past 3 months, 2. Have any serious diseases, 3. History of major psychiatric disorders within the past 2 years. 4. Have received an experimental drug/device within the past 30 days 5. Are pregnant or breastfeeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>